logo

INKT

MiNK Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.71 / 10
Netural

Fundamental analysis of INKT is neutral, with a composite score of 3.7/10. Key weaknesses include negative Asset-MV (-0.5066) and Revenue-MV (-0.2641) values, indicating sub-par asset base and revenue scale relative to market value. Profit-MV (0.4743) and Net income-Revenue (-0.1516) show modest positives but are offset by low inventory and current assets turnover ratios. Gross profit margin of 36.7% is decent yet insufficient to elevate the overall rating. Historical back-tests reveal limited upside potential, with one-month returns ranging from 0.22% to 11.66% across factors, reinforcing a selective, non-convincing outlook.

Fundamental(3.71)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score1/3
Weight10.63%
1M Return5.63%
Inventory turnover ratio
Value47.88
Score3/3
Weight9.74%
1M Return5.89%
Gross profit margin (%)
Value36.70
Score1/3
Weight0.31%
1M Return0.22%
Profit-MV
Value0.47
Score2/3
Weight14.88%
1M Return7.95%
Net income-Revenue
Value-0.15
Score2/3
Weight15.08%
1M Return8.04%
PB-ROE
Value2.67
Score3/3
Weight22.38%
1M Return11.66%
Current assets turnover ratio
Value1.78
Score2/3
Weight2.64%
1M Return1.75%
Fixed assets turnover ratio
Value7993.84
Score3/3
Weight2.25%
1M Return1.53%
Asset-MV
Value-0.51
Score0/3
Weight7.35%
1M Return4.17%
Cash-MV
Value-0.07
Score2/3
Weight14.74%
1M Return7.78%
Is INKT undervalued or overvalued?
  • INKT scores 3.71/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -4.40 P/E ratio, -3.67 P/B ratio, and 20.37% earnings growth, these metrics solidify its Netural investment rating.